通过骨架跃迁设计和合成诺如病毒抑制剂。
Design and synthesis of inhibitors of noroviruses by scaffold hopping.
机构信息
Department of Chemistry, Wichita State University, Wichita, KS 67260, United States.
出版信息
Bioorg Med Chem. 2011 Oct 1;19(19):5749-55. doi: 10.1016/j.bmc.2011.08.032. Epub 2011 Aug 22.
Abstract
A scaffold hopping strategy was employed to identify new chemotypes that inhibit noroviruses. The replacement of the cyclosulfamide scaffold by an array of heterocyclic scaffolds lead to the identification of additional series of compounds that possessed anti-norovirus activity in a cell-based replicon system.
摘要
采用支架跳跃策略来鉴定抑制诺如病毒的新型化学型。通过用一系列杂环支架替代环硫酰胺支架，在基于细胞的复制子系统中鉴定到了具有抗诺如病毒活性的额外系列化合物。
相似文献
1
Design and synthesis of inhibitors of noroviruses by scaffold hopping.
Bioorg Med Chem. 2011 Oct 1;19(19):5749-55. doi: 10.1016/j.bmc.2011.08.032. Epub 2011 Aug 22.
2
Cyclosulfamide-based derivatives as inhibitors of noroviruses.
Eur J Med Chem. 2012 Jan;47(1):59-64. doi: 10.1016/j.ejmech.2011.10.019. Epub 2011 Oct 20.
3
Discovery and Synthesis of Heterocyclic Carboxamide Derivatives as Potent Anti-norovirus Agents.
Chem Pharm Bull (Tokyo). 2016;64(5):465-75. doi: 10.1248/cpb.c16-00001.
4
Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.
Bioorg Med Chem Lett. 2018 Jul 1;28(12):2165-2170. doi: 10.1016/j.bmcl.2018.05.012. Epub 2018 May 8.
5
Potent norovirus inhibitors based on the acyclic sulfamide scaffold.
Bioorg Med Chem. 2012 Mar 15;20(6):2111-8. doi: 10.1016/j.bmc.2012.01.030. Epub 2012 Feb 2.
6
Potent inhibition of norovirus 3CL protease by peptidyl α-ketoamides and α-ketoheterocycles.
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4820-6. doi: 10.1016/j.bmcl.2012.05.055. Epub 2012 May 26.
7
The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81. doi: 10.1128/AAC.02546-13. Epub 2014 Jun 2.
8
Identification of novel non-nucleoside vinyl-stilbene analogs as potent norovirus replication inhibitors with a potential host-targeting mechanism.
Eur J Med Chem. 2019 Dec 15;184:111733. doi: 10.1016/j.ejmech.2019.111733. Epub 2019 Sep 26.
9
2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705.
Arch Virol. 2020 Nov;165(11):2605-2613. doi: 10.1007/s00705-020-04759-4. Epub 2020 Aug 8.
10
Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides.
Eur J Med Chem. 2020 Jun 1;195:112198. doi: 10.1016/j.ejmech.2020.112198. Epub 2020 Mar 7.
引用本文的文献
1
The Fellowship of Privileged Scaffolds-One Structure to Inhibit Them All.
Pharmaceuticals (Basel). 2021 Nov 16;14(11):1164. doi: 10.3390/ph14111164.
2
Structure-based design and synthesis of triazole-based macrocyclic inhibitors of norovirus protease: Structural, biochemical, spectroscopic, and antiviral studies.
Eur J Med Chem. 2016 Aug 25;119:300-18. doi: 10.1016/j.ejmech.2016.04.013. Epub 2016 Apr 25.
3
Anti-norovirus therapeutics: a patent review (2010-2015).
Expert Opin Ther Pat. 2016;26(3):297-308. doi: 10.1517/13543776.2016.1153065.
4
Recent Advances in the Discovery of Norovirus Therapeutics.
J Med Chem. 2015 Dec 24;58(24):9438-50. doi: 10.1021/acs.jmedchem.5b00762. Epub 2015 Aug 17.
5
Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.
J Med Chem. 2015 Apr 9;58(7):3144-55. doi: 10.1021/jm5019934. Epub 2015 Mar 19.
6
Treatment of norovirus infections: moving antivirals from the bench to the bedside.
Antiviral Res. 2014 May;105:80-91. doi: 10.1016/j.antiviral.2014.02.012. Epub 2014 Feb 25.
7
Structural and inhibitor studies of norovirus 3C-like proteases.
Virus Res. 2013 Dec 26;178(2):437-44. doi: 10.1016/j.virusres.2013.09.008. Epub 2013 Sep 17.
8
Potent inhibition of norovirus by dipeptidyl α-hydroxyphosphonate transition state mimics.
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5941-4. doi: 10.1016/j.bmcl.2013.08.073. Epub 2013 Aug 22.
9
Pediatric norovirus infection.
Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):285-90. doi: 10.1007/s10096-013-1967-9. Epub 2013 Sep 15.
10
Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3709-12. doi: 10.1016/j.bmcl.2013.05.021. Epub 2013 May 16.
本文引用的文献
1
Scaffold hopping.
Drug Discov Today Technol. 2004 Dec;1(3):217-24. doi: 10.1016/j.ddtec.2004.10.009.
2
Targeting norovirus infection-multivalent entry inhibitor design based on NMR experiments.
Chemistry. 2011 Jun 27;17(27):7442-53. doi: 10.1002/chem.201003432. Epub 2011 May 12.
3
"Double-click" protocol for synthesis of heterobifunctional multivalent ligands: toward a focused library of specific norovirus inhibitors.
Chemistry. 2011 Jun 27;17(27):7438-41. doi: 10.1002/chem.201003414. Epub 2011 Apr 5.
4
Noroviruses: The leading cause of gastroenteritis worldwide.
Discov Med. 2010 Jul;10(50):61-70.
5
Role of cholesterol pathways in norovirus replication.
J Virol. 2009 Sep;83(17):8587-95. doi: 10.1128/JVI.00005-09. Epub 2009 Jun 10.
6
Histone deacetylase inhibitors through click chemistry.
J Med Chem. 2008 Dec 11;51(23):7417-27. doi: 10.1021/jm8005355.
7
Triethylenetetramine penta- and hexa-acetamide ligands and their ytterbium complexes as paraCEST contrast agents for MRI.
Dalton Trans. 2008 Aug 21(31):4138-51. doi: 10.1039/b803557a. Epub 2008 Jun 12.
8
Synthesis of triazole-oxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity.
Bioorg Med Chem Lett. 2008 Sep 1;18(17):4868-71. doi: 10.1016/j.bmcl.2008.07.087. Epub 2008 Jul 24.
9
Norovirus gastroenteritis, increased understanding and future antiviral options.
Curr Opin Investig Drugs. 2008 Feb;9(2):146-51.
10
Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells.
J Virol. 2007 Nov;81(22):12111-8. doi: 10.1128/JVI.00560-07. Epub 2007 Sep 12.
Zotero 插件